Summarize Experience, Check Problems, Formulate Measures, Fully Deploy 2022 Work
Release time:
2022-02-08
News from our newspaper # February 25 and 26 , the group company held a business work analysis meeting to review and summarize the work situation in 2021 , arrange and deploy the work for the new year, and put forward work requirements. At the
meeting, various professional companies and directly affiliated enterprises made a report on the overall work situation of 2021 , focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and a work plan for 2021 . The functional departments and offices of the headquarters made a brief report on the annual work situation and the 2021 work plan. Xiang Chongping, deputy general manager of the group company, systematically combed the human resources development in 2021 from the current human resources structure, recruitment and resignation, training management, salary level and labor productivity, enterprise labor management, etc. Lan Xiaolong, head of finance, analyzed the company's profit and profit structure in 2021 , and pointed out the risk points that need attention in operation and management; chen Tianci, Chairman of the Board of Supervisors, analyzed the overall situation of technological transformation projects of various enterprises in the three years of 2019-2021 and the problems existing in the implementation process. Zhu Jianwei, secretary of the board of directors, analyzed the future risks that the company may encounter from the aspects of peak and listed companies in related industries in the year 2021 and the revision of listing rules. Yu Jianhong, general manager of
Group Company, made a comprehensive review of the company's operation in 2021 , made a comparative analysis of the main economic indicators of various industrial sectors, and pointed out that substantial progress has been made in the construction of key investment projects. Continue to strengthen management integration and effectively improve the management level; New achievements have been made in scientific and technological innovation and technological transformation. Overcoming the adverse effects of epidemic situation, power restriction and production restriction, efforts to expand sales; strengthen personnel training, selection and introduction, and optimize the salary system; to celebrate the centenary of the founding of the party and the study and education of party history as a starting point, strengthen party building and ideological and political construction, and enhance the cohesion and centripetal force of enterprises; strengthen the daily prevention and control of the new coronary pneumonia epidemic to ensure the safety and health of employees; and effectively enhance the corporate image, influence and reputation and other work highlights. In particular, the results of a series of technological transformation of Daye Peak are remarkable, many economic and technical indicators of Huang Ping Peak have reached the leading level in the industry, the market sales of Olopatadine Eye Drops, a new product of Peak Pharmaceutical, are progressing smoothly, and the legal work of the Office of the Board of Directors and the safety management measures of the Audit Performance Management Department are promoted. At the same time, it also focuses on some problems such as the decline in profit level, the slower-than-expected progress of new projects, the higher labor productivity of production lines, the insufficient innovation ability of research and development capability, the outdated ideas and thinking modes of management personnel, the unsatisfactory construction of talent team, and the rise of the phenomenon of "three violations " .
Based on the current macroeconomic situation and the future trends of various related industries, Yu Jianhong, on behalf of the Group, proposed the working policy of 2022 as "Reform, Breakthrough, Innovation, Development " , and around this policy, proposed the key work of 2022 , with emphasis, planning for the future development of "second curve " , breaking through the development bottleneck and quickly entering a new growth track is the company's current top priority. Under the company's existing system and mechanism, it is necessary to solve the three problems of development motivation, development concept and development ability, that is, to stimulate development motivation through cultural identity, value feelings and incentive evaluation. Advocate the development concept of "to be user-oriented, supported by technology, efficiency, value and mode leadership, and build a value chain or ecological circle " ; with excellent talents, efficient team and organizational structure to improve the enterprise to capture opportunities, operations integration, resource mining, risk identification and other development capabilities. It is hoped that management cadres at all levels will practice themselves, be strict with themselves, and vigorously advocate a truth-seeking and pragmatic work style. Management cadres will take the lead in telling the truth, doing practical things, seeking practical results, not engaging in formalism, and not making superficial articles; always maintain a spirit of forge ahead and never slack off The state of mind and the attitude of daring to break through and work, and resolutely put an end to the negative tendency of waiting, relying, relying, and demanding; vigorously advocate the work style of "to efficiency " , and resolutely put an end to the bad atmosphere of prevarication, discussion but not decision, and only saying but not doing. Vigorously advocate the work style of "raising enterprises as their own children " , put yourself in the position of seeking things, keep improving things, and strive to achieve perfection in every work; vigorously advocate "thrifty enterprise " work style, spend every penny on the blade, control every cost to the lowest, and improve the market competitiveness of enterprises and products. In his concluding speech, Jiang Xiaomeng, chairman of
Group Company, expressed his affirmation and gratitude to all enterprises for their efforts and achievements in 2021 , commented on their resource acquisition ability, team morale, internal system construction, employee centripetal force, etc., and hoped that all enterprise management teams would seriously reflect, efforts to improve the communication ability at work, the determination and responsibility of handling affairs, and be able to discover and solve problems with a more systematic thinking and a more comprehensive perspective. Jiang Xiaomeng pointed out that in the future work, "cost reduction " will always be the main tone and the most basic competitiveness for enterprises to participate in market competition. The intelligence and digitization of production enterprises for the purpose of improving labor productivity is the general trend, and we must speed up the in-depth development. Innovation work such as technological transformation and new drug research and development should be strengthened and accelerated; new investment projects need to spend more energy to accelerate. He emphasized that management teams at all levels must unify their thinking, clarify management relationships, and establish a sound system in order to better improve the team's combat effectiveness and work passion, and promote the better development of the enterprise. (Reporter Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31